Rocket Software and T-Systems partner on data transfer delay reduction project
Rocket Software, the US-based software firm, and T-Systems, the German IT company, have partnered to reduce the delay times associated with data transferring.
The firms have combined their capabilities to create a single solution that can reduce the time of manual data exchange tasks by 90%.
“We redesigned our entire COMPDM product when we realised the potential of integrating with Rocket Software’s TRUfusion Enterprise,” said Martin Frenzel, product manager at T-Systems.
“TRUfusion Enterprise automates all of the workflow processes that were taking place manually between suppliers, while providing an exceptionally high level of automation and security.”
“It was clear that by working together we could drastically cut the time taken to complete data transfers with PLM systems at both ends, and the partnership works incredibly well – it’s like a hand in a glove.”
“It’s important that Rocket has a global reach as wide as our own, so we can serve manufacturers across the world on an equal basis. There aren’t many other companies who can do that.”
“One of the keys to the success of the collaboration is that customers can implement a solution to address a complex, expensive, but essential business process,” said Martyn Davies, director of product management at Rocket Software.
“Import/export processes from PLMs can be very complex, but with the combined TRUfusion Enterprise and COMPDM solution, we are seeing times reduce from one or two hours to 5-10 minutes.”
“When you’re talking about 30-50 thousand transactions a year, that equates to a lot of time. Even when we aren’t dealing with PLM workflows, customers are reducing their time taken from 15-30 minutes down to one or two.”
IMF: Variants Can Still Hurt Manufacturing Recovery
After a year of on-and-off manufacturing in the US, UK, and the eurozone, demand for goods surged early last week. Factories set growth records in April and May, suppliers started to recover, and US crude hit its highest price point since pre-COVID. As vaccination efforts immunise much of the US and UK populations, manufacturers are now able to fully ramp up their supply chains. In fact, GDP growth could approach double-digits by 2022.
Now, the ISM productivity measure has surpassed the 50-point mark that separates industry expansion from contraction. Since U.S. president Biden passed his US$1.9tn stimulus package and the UK purchasing managers index (PMI) increased to 65.6, both sides of the Atlantic are facing a much-welcomed manufacturing recovery.
Lingering Concerns Over COVID
Even as Spain, France, Italy, and Germany race to catch up, and mining companies pushed the FTSE 100 index of list shares to a monthly high of 7,129, some say that UK and US markets still suffer from a lack of confidence in raw material supplies. Yes, the Dow Jones has made up its 19,173-point crash of March 2020, and MSCI’s global stock index is at an all-time high.
Yet manufacturers around the world realise that these wins will be short-lived until pandemic supply chain bottlenecks are solved. If we keep the status quo, consumers will pay the price. In April, inflation in Germany reached 2.4%, and across the EU’s 19 member countries, overall prices have increased at an unusual pace. Some ask: Is this true recovery?
IMF: Current Boom Could Falter
Even as Elon Musk tweeted about chip shortages forcing Tesla to raise its prices, UK mining demand skyrocketed; housing markets lifted; and the pound sterling gained value. The International Monetary Fund (IMF), however, cautioned that manufacturing recovery won’t last long if COVID mutates into forms our vaccinations can’t touch. Kristalina Georgieva, Washington’s IMF director, noted that fewer than 1% of African citizens have been vaccinated: “Worldwide access to vaccines offers the best hope for stopping the coronavirus pandemic, saving lives, and securing a broad-based economic recovery”.
Across the globe, manufacturing companies are keeping a watchful eye on new developments in the spread of COVID. Though US FDA officials don’t think we’ll have to “start at square one” with new vaccines, the March 2021 World Economic Outlook states that “high uncertainty” surrounds the projected 6% global growth. Continued manufacturing success will in large part depend on “the path of the pandemic, the effectiveness of policy support, and the evolution of financial conditions”.
Mathias Cormann, secretary-general of the Organisation for Economic Co-Operation and Development (OECD) concurred—without global immunisation, the estimated economic boom expected by 2025 could go kaput. “We need to...pursue an all-out effort to reach the entire world population”, Australia’s finance minister added. US$50bn to end COVID across the world, they imply, is a small investment to restart our economies.